Recent developments in the field of FRα-based therapies such as chimeric antigen receptor T (CAR-T) cell therapy in acute myeloid leukemia [32], triple-negative breast cancer [33], gastric cancer [34], or ovarian cancer [35] are very promising. This evidence concerns the gene FOLR1 and ovarian carcinoma.